

# Intraoperative Red Blood Cell Transfusion in Infant Heart Transplant Patients Is Not Associated with Worsened Outcomes

Harmony F. Carter, MD,\* Carol Lau, MD,\* David Juma, MPH,† Briana Wells, MS,† and Richard L. Applegate II, MD\*

**BACKGROUND:** Red blood cell (RBC) transfusion is common during infant cardiac surgery. A previous report of pediatric heart transplant recipients showed that increased RBC transfusion volume was independently associated with increased length of intensive care unit stay. It is unclear whether transfusion to infants as a subgroup carries similar risks. This study investigated relationships between intraoperative RBC transfusion during heart transplantation and postoperative length of stay (LOS), morbidity, and mortality in infants.

**METHODS:** Retrospective analysis of medical records from infants <1 year old undergoing primary heart transplantation at Loma Linda University Medical Center from 1985 to 2012 was conducted. Exclusion criteria included preoperative exchange transfusion or extracorporeal membrane oxygenation. Data sought included patient characteristics; intraoperative RBC transfusion volume and cardiopulmonary bypass details; and postoperative vasoactive support, ventilator support, morbidity, LOS, and 30-day mortality. The relationship of RBC transfusion volume (mL/kg) to these postoperative variables was assessed by univariate analysis. Multiple regression analysis of postoperative LOS included variables that were independent predictors of LOS or associated with  $\geq 10\%$  change in the  $\beta$ -estimate for RBC effect.

**RESULTS:** Data from 307 infants showed that most (66.8%) had single-ventricle physiology. Median age at transplant was 50 days, weight 3.95 kg, and intraoperative transfusion volume 109 mL/kg. Transfusion volume was inversely related to age and weight. Median postoperative LOS was 18.2 days. Univariate linear regression analysis of transfused volume showed no relationship to log-transformed postoperative LOS ( $F(1,305) = 0.00$ ;  $P = 0.960$ ;  $R^2 = 0.000$ ;  $\beta$ -coefficient = 0.004; 95% confidence interval =  $-0.1542$  to  $0.1623$ ). Transfused volume was not related to 30-day mortality (difference  $-0.162$ ;  $-0.048$  to  $0.371$  mL/kg;  $P = 0.112$ ) or to postoperative ventilator support ( $R^2 = 0.047$ ), but was greater in patients who required reoperation (difference  $-0.246$ ;  $-0.494$  to  $-0.025$ ;  $P = 0.004$ ). Multiple regression analysis for all patients revealed age, preoperative ventilator support, prolonged postoperative ventilatory or vasoactive support, transplant year, and 30-day mortality, but not major adverse events, to be significant confounding variables. Adjusting for these variables, transfused volume was not associated with prolonged postoperative LOS.

**CONCLUSIONS:** In contrast to a prior report, we found no correlation between intraoperative RBC transfusion and postoperative LOS when studying only infants. Infants have maturing organ systems, less physiologic reserve, and increased surgical blood loss (evaluated as mL/kg) during cardiac surgery than their larger, older counterparts, distinguishing them from the general pediatric population. These differences require additional studies to determine the outcome impact of transfusion strategies in the infant subgroup. (Anesth Analg 2016;122:1567–77)

Preexisting anemia and surgical blood loss make red blood cell (RBC) transfusion a common and necessary perioperative intervention for the pediatric

cardiac surgical patient. Despite ongoing surgical losses, oxygen-carrying capacity must be maintained. For small infants requiring cardiopulmonary bypass (CPB), the pump priming volume is quite large relative to the patient's blood volume; the resultant hemodilution often requires RBC transfusion.<sup>1,2</sup> Although transfusions may be lifesaving, there is increasing concern regarding the deleterious effects of blood product administration. Some studies in the pediatric population have associated perioperative RBC transfusions with increased postoperative morbidity.<sup>3–10</sup> In a retrospective study of RBC transfusion to heart transplant recipients  $\leq 18$  years old, multiple regression analysis revealed that increased RBC transfusion volume was independently associated with increased length of intensive care unit (ICU) stay and higher initial inotrope scores.<sup>5</sup> Transfusion volume  $>60$  mL/kg was associated with an increased risk of major adverse events. Although a large prospective noninferiority trial in stable critically ill pediatric ICU patients<sup>11</sup> showed no significant outcome differences with a restrictive transfusion strategy, subgroup

From the \*Department of Anesthesiology, Loma Linda University School of Medicine, Loma Linda, California; and †Research Consulting Group, Loma Linda University, Loma Linda, California.

Richard L. Applegate II, MD, is currently affiliated with the Department of Anesthesiology and Pain Medicine, University of California Davis, Sacramento, California.

Accepted for publication January 14, 2016.

Funding: This work was entirely funded by the Loma Linda University School of Medicine Department of Anesthesiology.

The authors declare no conflicts of interest.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website ([www.anesthesia-analgia.org](http://www.anesthesia-analgia.org)).

Reprints will not be available from the authors.

Address correspondence to Richard L. Applegate II, MD, Department of Anesthesiology and Pain Medicine, University of California Davis, 4150 V St., PSSB 1200, Sacramento, CA 95817. Address e-mail to [rapplegate@ucdavis.edu](mailto:rapplegate@ucdavis.edu).

Copyright © 2016 International Anesthesia Research Society  
DOI: 10.1213/ANE.0000000000001241

analysis of post-cardiac surgery patients showed an upward trend toward more organ dysfunction.<sup>12</sup> A unique concern for transplant recipients is the risk of allosensitization after transfusion.<sup>13,14</sup>

The International Society for Heart and Lung Transplantation Registry reports that approximately 25% of pediatric heart transplant recipients are infants younger than 1 year.<sup>15</sup> Many physiologic changes occur during the first 12 months of life, distinguishing infants from the general pediatric population. Infant heart transplant recipients may have a relative physiologic immunodeficiency,<sup>16-18</sup> which could affect their response to RBC transfusion. They are also more likely to undergo cardiac transplant for cyanotic heart disease and clinically need higher baseline hemoglobin levels. In the light of these differences, this study aims to evaluate the outcome impact of intraoperative RBC transfusion to infant heart transplant surgery recipients on postoperative length of stay (LOS), morbidity, and mortality in this unique pediatric subgroup.

## METHODS

After IRB approval and waiver of consent, charts of all pediatric patients <1 year of age undergoing heart transplantation at Loma Linda University Medical Center from 1985 to 2012 were reviewed, with data collection and preliminary analysis completed in 2013. At this institution, CPB protocols and transfusion strategies for infant heart transplant recipients have remained fairly stable over the past 3 decades, with important changes as noted. The perfusion protocol included active surface cooling during line placement and surgical dissection, hemodilution on initiation of CPB, deep hypothermia during low-flow states or circulatory arrest,<sup>19</sup> and  $\alpha$ -STAT management to maintain capillary microcirculation integrity,<sup>20</sup> while relying on dissolved oxygen to supply the cerebral metabolic demands.<sup>21</sup> The CPB prime included calcium-free crystalloid prime and 100 mL of albumin 25% added to maintain osmolality for a total volume of approximately 550 mL. The circuit included a DeBakey roller pump, arterial filter, and in-line hemoconcentrator. After appropriate heparinization and cannulation, CPB was initiated with rapid cooling (over approximately 15 minutes) to 18°C. Initially longer, deep hypothermic circulatory arrest times were used; however, with increased experience, the deep hypothermic circulatory arrest times decreased. More recent cases were done with selective cerebral perfusion. Upon rewarming, continuous ultrafiltration was initiated (reversing hemodilution by removing approximately 500–800 mL ultrafiltrate). Washed irradiated RBCs were transfused per institutional protocol during and after CPB, providing further hemodilution correction during rewarming and replacing ongoing blood loss with the goal hematocrit between 30% and 35%. To eliminate the confounding effect of significant blood product exposure before surgery, exclusion criteria included prior heart transplant, preoperative extracorporeal membrane oxygenation, and preoperative exchange transfusions.

Total intraoperative RBC transfusion volumes (mL/kg) were extracted from medical records, blood bank records, and the Loma Linda University International Heart Institute database. Preoperative, intraoperative, and postoperative patient characteristics were recorded. Vasoactive

support included the use of either inotrope or vasopressor infusions. Postoperative duration of mechanical ventilation was defined from the end of surgery to the first successful tracheal extubation lasting for at least 24 hours.

## Statistical Analysis

The primary outcome measure chosen for this study was the relationship between RBC transfusion and posttransplant LOS, because this summates postoperative morbidity. We did not use 30-day mortality as our primary outcome because the number who died within 30 days after transplant was 25. This limits our ability to adjust for potential confounding variables and other significant predictors of 30-day mortality. LOS was defined as the time from postoperative ICU admission until discharge home. It is a standard practice at this institution to discharge patients home directly from the pediatric cardiac ICU. Histograms and Kolmogorov-Smirnov test statistics were examined to determine whether the distribution of LOS was reasonably modeled by a normal distribution on the original or log scale. The log transformation of LOS better approximated normality than the untransformed LOS. Year of transplant was dichotomized based on implementation of selective cerebral perfusion in 1995. Transfused volume was converted to 100 mL/kg to facilitate data analysis and comparison with clinical transfusion practices.

Secondary outcomes examined included postoperative major adverse events, defined as cardiac arrest, primary open chest (open sternum at the conclusion of primary operation), reoperation (additional postoperative surgical intervention), new dialysis, or new onset of seizures. Other secondary outcomes were duration of postoperative vasoactive support, postoperative ventilator days, and 30-day mortality. Categorical data are given as number (%), and differences were compared by using the Wald test for proportions. Continuous data were analyzed for normal distribution by the Shapiro-Wilk test, with  $P < 0.05$  indicating that the data were not normally distributed. Continuous data are given as mean or median and 95% confidence interval as appropriate to the data. Differences between categorical variables for continuous data that were not normally distributed were compared by the Hodges-Lehmann method assuming data symmetry and given as difference and 95% confidence interval.

Initial univariate analysis was conducted to evaluate the relationships among RBC transfusion volume, log LOS, and the secondary outcomes. Identified significant confounding variables were subjected to multiple regression analysis to evaluate the effects of confounding factors on LOS. Variables were included in the model if they were independent predictors of LOS or if they were associated with a  $\geq 10\%$  change in the  $\beta$ -estimate for RBC effect. All regression assumptions were checked by visually investigating residual plots. Linearity was additionally assessed via partial regression plots between the predictors and the log-transformed LOS. Results are presented as  $\beta$ -coefficients and their SE. Significance was set at 0.05. The analysis was performed using SAS/STAT software, version 9.4 of the SAS System for Windows, SAS Institute Inc., Cary, NC.

## RESULTS

A total of 313 infants who underwent primary cardiac transplant were identified. Six were excluded for missing data, yielding 307 study patients. Characteristics of those who survived >30 days after transplant ( $n = 282$ ) are compared with those who died within 30 days of transplant ( $n = 25$ ) in Table 1. Median age at transplant was 50 days and weight was 3.95 kg. Most infants had single-ventricle physiology (66.8%); cardiomyopathy and other complex congenital cardiac defects accounted for most of the remaining patients. Preoperative prostaglandin infusion was common, and about one-third required ventilator support before transplantation. The mean preoperative hemoglobin was 13.1 g/dL (range, 7.8–19.5 g/dL). Median postoperative LOS was 18.2 days. Two patients were discharged home with continued mechanical ventilation (one had a 222-day LOS but required ventilator support for 423 days).

Transfusion volume was inversely related to age and weight (Fig. 1). The median volume of RBCs transfused during surgery was 109 mL/kg (range, 28–328 mL/kg). All patients were transfused during CPB, with the majority receiving 1 to 2 units; 275 patients required additional transfusion after separation from CPB, while 32 patients did not. As shown in Figure 2, most RBC transfusion occurred during CPB. The first postoperative hemoglobin recorded averaged 12.0 g/dL (range, 7.4–18.1 g/dL). Postoperative LOS was evaluated and found to be heavily right skewed (Kolmogorov-Smirnov test: 0.1960;  $P$  value < 0.010; mean = 24.21 versus median = 18). LOS was log transformed to better approximate normality. Univariate analysis showed no relationship of log LOS to RBC transfusion volume (Fig. 3). Univariate analyses of preoperative and postoperative characteristics compared with RBC transfusion are summarized in Tables 2 and 3 and with log LOS in Tables 4 and 5.

After univariate and bivariate analyses, multiple regression analysis was performed in a stepwise manner. Model development steps for all transplant recipients and for only those who survived >30 days after transplant are shown in the Supplemental Digital Content, Supplemental Digital Content Tables 1 and 2 (<http://links.lww.com/AA/B381>). Multiple regression analysis (Table 6) revealed age, year of transplant group, preoperative ventilator support, and prolonged postoperative ventilatory or vasoactive support to be significant confounding variables for log LOS. Multiple regression analysis showed that the occurrence of one or more postoperative major adverse events was not a significant predictor of LOS in the presence of the other covariates; thus, major adverse events were excluded from the final model (Supplemental Digital Content, <http://links.lww.com/AA/B381>). Age and weight had a direct linear correlation ( $r = 0.8157$ ;  $P < 0.0001$ ), and therefore, only age was used. After adjusting for all identified confounding variables, volume of RBC transfusion was not significantly associated with log-transformed LOS ( $-0.126$ ;  $-0.274$  to  $0.022$ ;  $P = 0.098$ ). Increased age at transplant was associated with a reduction in LOS ( $-0.093$ ;  $-0.157$  to  $0.0289$ ;  $P = 0.0053$ ), whereas increased duration of postoperative ventilation was associated with longer LOS ( $0.261$ ;  $0.184$ – $0.338$ ;  $P < 0.0001$ ). Similarly, multiple regression analysis of

only those who survived >30 days after transplant showed that RBC transfusion volume had no effect on LOS when confounding variables are considered (Table 7). The 30-day postoperative mortality was 8.87% (25 cases), thus limiting logistic regression analyses to univariate and bivariate models. Univariate and bivariate logistic regression modeling of variables related to 30-day mortality are shown in Tables 8 and 9.

## DISCUSSION



RBC transfusion is a medical intervention in which the risks and benefits must be carefully weighed. Noninfectious risks account for the majority of fatal transfusion complications; most pediatric reports are associated with human errors, such as overtransfusion and misunderstanding neonatal requirements.<sup>22</sup> Withholding transfusion may be equally dangerous, because a significant portion of intraoperative pediatric cardiac arrests is associated with inadequate resuscitation of surgical bleeding.<sup>23</sup> We found no positive correlation between intraoperative RBC transfusion volume and increased LOS by univariate analysis or multiple regression analysis ( $-0.126$ ;  $-0.274$  to  $0.022$ ;  $P = 0.098$ ). Univariate analysis showed that infants with delayed chest closure or reoperation for other surgical reasons had larger intraoperative RBC transfusion volumes at the time of transplant, but we did not find significant intraoperative RBC transfusion volume differences in infants who required prolonged postoperative ventilator or vasopressor support or in those who developed new seizures postoperatively, new need for dialysis, cardiac arrest, or death within 30 days of transplant (Tables 2 and 3). Furthermore, multiple regression analysis showed that postoperative major adverse events were not a significant predictor of LOS in the presence of the other covariates (Supplemental Digital Content, <http://links.lww.com/AA/B381>). Our findings differ from a previous report.<sup>5</sup> Several factors may have contributed to this difference.

Infants  $\leq 30$  days of age are at greatest risk for blood loss during pediatric cardiac surgery, with blood loss varying inversely with age and notable differences between age groups.<sup>24</sup> Although the CPB perfusion strategy in this study was different (hemodilution with large volume acellular prime, followed by hemoconcentration during rewarming though continuous ultrafiltration and concurrent RBC transfusion), the median transfusion volume we found (109 mL/kg) was not significantly greater than that reported in infants <12 months of age in a prior report ( $95 \pm 53$  mL/kg).<sup>5</sup> That group reported RBC transfusion volume, but not age, to be independently associated with the studied outcomes. They also found that major adverse events (new dialysis, sepsis, graft failure, extracorporeal membrane oxygenation, and open chest) were associated with larger transfusion volumes. In contrast, we found that patient age and weight were directly linked and were independent predictors of LOS, whereas RBC transfusion volume was not. Younger, smaller infants had longer LOS and prolonged vasoactive and ventilator support, possibly reflecting organ system maturation during the first year of life. The outcome differences between studies may highlight a sampling bias: our analysis was restricted to infants up to 12 months of age


**Table 1. Characteristics of Infant Heart Transplant Recipients <1 Year of Age Who Survived >30 Days (Survivors) Compared with Those Who Died Within 30 Days (Nonsurvivors) After Heart Transplant**

	Survivors (n = 282)	Nonsurvivors (n = 25)	Difference (95% CI)	P value
<b>Patient characteristics</b>				
Sex female, n (%)	115 (40.8)	12 (48.0)	-7.22% (-26.99% to 12.39%)	0.467
Age at transplant days	48.6 (41.3 to 56.7)	64.8 (43.0 to 97.3)	8.0	0.450
Median (95% CI)		7 to 254		
Range	0 to 345		-12.0 to 31.0	
Weight at transplant (kg)	3.95 (3.80 to 4.10)	3.97 (3.61 to 4.32)	-0.88	0.747
Median (95% CI)		2.16 to 7.03		
Range	2.05 to 10.40		-0.58 to 0.40	0.472
Cardiac defect leading to transplant, n (%)				
Single-ventricle physiology	192 (68.1)	19 (76.0)		
Complex congenital heart disease	44 (15.6)	3 (12.0)		
Cardiomyopathy	42 (14.9)	2 (8.0)		
Other	4 (1.42)	1 (4.0)		
Year of transplant group (1985–1994), n (%)	169 (59.9)	19 (76.0)		
<b>Preoperative characteristics</b>				
Vasoactive support, n (%)	50 (17.73)	4 (16.0)	-1.73% (-14.756% to 15.878%)	0.943
Ventilator support, n (%)	93 (32.98)	6 (24.0)	-8.98% (-24.59% to 10.24%)	0.420
Prostaglandin infusion, n (%)	192 (68.09)	18 (72.0)	3.92% (-15.65 to 20.47%)	0.793
Prior sternotomy, n (%)	40 (14.18)	5 (20.0)	0.058% (-8.42 to 23.99%)	0.387
Preoperative hemoglobin (g/dL), mean (CI)	13.2 (12.9 to 13.4)	12.7 (11.9 to 13.5)	-0.30	0.225
Range (g/dL)	7.8 to 19.5	9.3 to 15.3	-1.20 to 0.40	
<b>Intraoperative characteristics</b>				
Donor organ ischemic time (min), median (CI)	270.0 (251.5 to 289.2)	235.7 (170.8 to 309.8)	-23.0	0.393
Range	60 to 595	90 to 539	-81.0 to 29.0	
Total cardiopulmonary bypass time (min), median (CI)	95.5 (89.3 to 104.0)	99.9 (85.6 to 124.0)	1.0	0.842
Range	38 to 235	57 to 281	-14.0 to 16.0	
Circulatory arrest time (min), median (CI)	43.4 (40.2 to 45.6)	49.3 (35.6 to 54.3)	6.0	0.076
Range	0 to 82	0 to 110	0 to 14.0	
<b>Intraoperative transfusion</b>				
Red blood cell transfusion volume (mL/kg), median (CI)	107.6 (101.2 to 115.9)	126.2 (106.5 to 144.2)	15.9	0.225
Range	27.7 to 311.1	52.5 to 328.2	-5.41 to 37.09	
<b>Postoperative characteristics, n = 307</b>				
Length of stay (d), median (CI)	19.1 (17.6 to 20.6)	10.1 (5.6 to 14.2)	-11.0	<0.0001
Range	6 to 222	0 to 30	-14.0 to -7.0	
Ventilator (d), median (CI)	3.1 (2.7 to 3.7)	3.5 (2.0 to 5.5)	0.0	0.928
Range	0 to 423	0 to 17	-1.0 to 1.0	
Vasoactive support (d), median (CI)	4.1 (3.8 to 4.7)	4.2 (2.5 to 6.4)	0.0	0.994
Range	0 to 129	0 to 17	-1.0 to 1.0	
Hemoglobin (g/dL), mean (CI)	12.2 (12.0 to 12.5)	12.5 (11.8 to 13.2)	0.26	0.522
Range	7.4 to 18.1	9.6 to 16.9	-0.50 to 1.03	
<b>Postoperative complications, n (%)</b>				
Cardiac arrest	24 (8.51)	14 (56.0)	-47.49% (-65.78% to -27.72%)	<0.0001
Primary open chest or reoperation	30 (10.64)	10 (40.0)	29.36% (10.94% to 48.71%)	0.002
Reoperation	12 (4.26)	11 (44.0)	36.19% (17.34% to 55.36%)	0.0002
New dialysis	22 (7.80)	3 (12.0)	-7.50% (-19.08% to 9.27%)	0.498
New seizures	55 (19.50)			

Comparison of characteristics in infants <1 year of age who survived >30 days (survivors) compared with those who died within 30 days (nonsurvivors) after heart transplant. Data were tested for normal distribution using the Shapiro-Wilk test, with  $P < 0.05$  indicating that data were not normally distributed. Normally distributed data are given as mean; 95% confidence interval (CI) and differences were tested using the t test. Data that were not normally distributed are given as median; smoothed empirical quantiles and differences were compared using the Hodges-Lehmann method assuming data symmetry. Categorical data are given as number (%), and differences were compared using the Wald test for proportions. Year of transplant was grouped based on implementation of selective cerebral perfusion during bypass starting in 1995.




**Figure 1.** Intraoperative red blood cell (RBC) transfusion volume in 307 infant heart transplant recipients <1 year of age was inversely related to patient age (A) and weight (B).



**Figure 2.** Comparison of intraoperative red blood cell (RBC) transfusion volume (median, bar indicates 95% confidence interval) given to 307 infant heart transplant recipients <1 year of age. The majority of the intraoperative RBC volume was administered during cardiopulmonary bypass (CPB).

(median age 50 days), whereas the prior report<sup>5</sup> included pediatric cardiac transplant recipients  $\leq 18$  years of age (median age 11.7 years). Not surprisingly, infants in that report received the largest blood transfusion volume in milliliters per kilograms; only those weighing  $>30$  kg averaged transfusion volumes  $<15$  mL/kg, placing the majority of transplant recipients  $<30$  kg in the high-exposure group.

Although age was not shown to be statistically significant in that report, it had obvious clinical significance; this discrepancy was likely attributable to age differences because only a small number of infants and small children were included in that report. Furthermore, we did not find relationships between transfused volume and several postoperative major adverse events, prolonged postoperative ventilatory



**Figure 3.** Postoperative hospital length of stay (LOS) in 307 infant heart transplant recipients <1 year of age. Univariate analysis showed that log LOS was not related to the red blood cell (RBC) volume transfused during surgery.

**Table 2. Analysis of Relationship Between Patient Characteristics and Red Blood Cell Transfusion: Linear Regression Analysis of Continuous Variables to Intraoperative Red Blood Cell Transfusion (100 mL/kg)**

Characteristic	Slope	Intercept	r <sup>2</sup>
Log age (d)	-0.216	2.0005	0.208
Log weight (kg)	-1.189	2.840	0.485
Preoperative hemoglobin (g/dL)	0.0351	0.703	0.019
Donor organ ischemic time (min)	-0.00007	1.186	0.0003
Total cardiopulmonary bypass time (min)	-0.00265	1.457	0.051
Circulatory arrest time (min)	0.0114	0.741	0.252
Postoperative hemoglobin (g/dL)	0.0638	0.381	0.062
Log postoperative ventilator support (d)	0.110	1.040	0.047
Log postoperative vasoactive support (d)	0.189	0.915	0.080
Log length of stay (d)	0.002	1.16	0.0000

Intraoperative red blood cell transfusion (100 mL/kg) was compared with patient and perioperative characteristics. Continuous data were compared by linear regression.

or vasoactive support, or death within 30 days of transplant. We postulate that the infant’s immature immune system<sup>16–18</sup> and transfusion of washed irradiated RBCs may not elicit the same inflammatory and immunomodulatory effects seen with transfusions to older children and adults, but this will require further investigation.

Previous investigators found that increased transfusion during CPB was associated with excessive postoperative bleeding and worsened outcomes after pediatric cardiac surgery.<sup>25</sup> Those investigators reported notable risk factors for excessive postoperative bleeding, which included age and weight. Those with excessive bleeding averaged an age of 138 days and a weight of 5.3 kg compared with an age of 657 days and weight of 10.3 kg in those without excessive bleeding.<sup>25</sup> Similarly, infants that required intraoperative and postoperative transfusions despite undergoing a blood-sparing approach to pediatric cardiac surgery had worsened outcomes (increased ventilator days and ICU LOS) compared with nontransfused infants.<sup>26,27</sup> However, considering the uniform intraoperative transfusion protocol

**Table 3. Analysis of Relationship Between Patient Characteristics and Red Blood Cell Transfusion: Categorical Variables Yes Versus No Unless Otherwise Indicated Compared with Intraoperative Red Blood Cell Transfusion (100 mL/kg)**

Variable	Hodges-Lehmann Difference	95% CI	P value
Sex (female versus male)	-0.072	-0.182 to 0.038	0.197
Cardiac defect leading to transplant single ventricle versus other diagnoses	0.035	0.080 to 0.152	0.532
Intubated before transplant	-0.026	0.143 to 0.086	0.648
Prior sternotomy	0.167	0.017 to 0.315	0.032
Prostaglandin infusion	-0.358	-0.458 to -0.258	<0.0001
Postoperative cardiac arrest	-0.139	-0.287 to 0.039	0.123
Primary open chest or reoperation	-0.246	-0.494 to -0.025	0.004
New postoperative dialysis	-0.140	-0.319 to 0.040	0.118
New postoperative seizures	0.021	-0.111 to 0.149	0.790
30-day mortality	-0.162	-0.048 to 0.371	0.112

Intraoperative red blood cell transfusion (100 mL/kg) was compared with patient and perioperative characteristics. Differences in continuous data between categorical variables were compared by the Hodges-Lehmann method assuming data symmetry.

and maximal blood-sparing approach (including miniaturized CPB circuit down to 95-mL priming volume), it is possible that the need for RBC transfusion is a marker for, rather than the cause of, patient morbidity. Another retrospective study of infants undergoing heart surgery reported that a comprehensive blood conservation strategy, including reduction of circuit priming volume from 600 to 300 mL, was associated with significant decreases in intraoperative and postoperative blood transfusion, inotropic scores, ventilator duration, and hospital LOS (despite lower hemoglobin values after implementation).<sup>28</sup> However, it is possible that the other improvements in CPB and patient management implemented in this study contributed favorably to those outcome differences.

Many retrospective studies have linked increased blood transfusions with worsened outcomes. Perhaps the underlying association is the severity of surgical bleeding and preoperative morbidity rather than the amount of blood

**Table 4. Analysis of Relationship Between Patient Characteristics and Length of Stay: Linear Regression Analysis of Continuous Variables to Log Length of Stay**

Characteristic	Slope	Intercept	R <sup>2</sup>
Log age (d)	-0.1567	3.545	0.0556
Log weight (kg)	-0.3240	3.395	0.0183
Year of transplant	-0.0053	13.460	0.0024
Preoperative hemoglobin (g/dL)	0.0338	2.485	0.0092
Donor organ ischemic time (min)	0.0003	2.846	0.0033
Total cardiopulmonary bypass time (min)	-0.0019	3.152	0.0437
Circulatory arrest time (min)	0.0003	2.928	0.0001
Red blood cell transfusion (100 mL/kg)	0.0004	2.9345	0.0000
Postoperative hemoglobin (g/dL)	-0.0068	3.012	0.0004
Log postoperative ventilator support (d)	0.3411	2.486	0.131
Postoperative vasoactive support (d)	0.0260	2.814	0.093

Length of stay (LOS) compared with patient and perioperative characteristics. The log transformation of LOS better approximated normality than the untransformed LOS. Continuous data were compared with log LOS by linear regression.

**Table 5. Analysis of Relationship Between Patient Characteristics and Length of Stay: Categorical Variables Yes Versus No Unless Otherwise Indicated Compared With Length of Stay (d)**

Variable	Hodges-Lehmann difference	95% CI	P value
Sex, female versus male	-0.134	-0.262 to 0.000	0.260
Cardiac defect leading to transplant single ventricle versus other diagnosis	0.000	-0.165 to 0.113	0.271
Intubated before transplant	-0.405	-0.547 to -0.288	<0.0001
Prior sternotomy	0.310	0.143 to 0.511	0.0054
Prostaglandin infusion	-0.241	-0.377 to -0.105	0.0186
Cardiac arrest	-0.053	-0.288 to 0.211	0.492
Primary open chest or reoperation	-0.191	-0.427 to 0.065	0.349
New postoperative dialysis	-0.192	-0.446 to 0.077	0.244
New postoperative seizures	-0.074	-0.228 to 0.080	0.355
30-day mortality	0.847	0.499 to 1.253	<0.0001

Length of stay (LOS) compared with patient and perioperative characteristics. The log transformation of LOS better approximated normality than the untransformed LOS. Differences in continuous data between categorical variables were compared by Hodges-Lehmann assuming data symmetry.

transfused,<sup>29</sup> because 1 study found the volume of chest tube drainage at 24 hours to be the strongest independent predictor of mortality.<sup>30</sup> Underlying confounders are difficult to tease out in these retrospective studies. All-cause mortality and secondary outcomes (stroke, myocardial infarction, acute renal failure, infections, arrhythmias, bleeding, ICU, and hospital LOS) were evaluated in a meta-analysis of 21 prospective randomized controlled trials involving transfusion protocols during cardiac or vascular surgery, which randomized to either a restrictive or liberal transfusion study arm (including studies using acute normovolemic hemodilution as a restrictive approach). Four of the studies involved pediatric patients.<sup>31</sup> Pediatric patients in the restrictive study arms used significantly less blood, but there were no statistically significant differences in mortality or secondary outcomes. Of note, both ICU and hospital LOS were increased by 1 day

**Table 6. Multiple Regression Analysis of Infant Heart Transplant Recipients on Log Length of Stay**

Variable	β	Confidence interval	P value
RBC (100 mL/kg)	-0.126	-0.274 to 0.022	0.098
1995–2012 vs 1985–1994	0.148	0.005 to 0.290	<b>0.0425</b>
Log age (d)	-0.093	-0.157 to -0.0289	<b>0.0046</b>
Intubated before transplant	0.147	0.009 to 0.284	<b>0.0367</b>
Log postoperative ventilator support (d)	0.261	0.184 to 0.338	<b>&lt;0.0001</b>
Log postoperative vasoactive support (d)	0.147	0.049 to 0.245	<b>0.0035</b>
30-Day mortality	-1.004	-1.222 to -0.785	<b>&lt;0.0001</b>
Intercept	2.929	2.538 to 3.320	<b>&lt;0.0001</b>

Bold indicates significance; adjusted R<sup>2</sup> = 0.4549. Final multiple regression model of factors influencing log length of stay (LOS) for 307 infants <1 year undergoing cardiac transplantation included in the study. The model indicates that RBC transfusion has no impact on LOS. Year of transplant group had an effect on LOS for all patients, but not when those who died within 30 days of transplant were excluded (Table 7). For every 10% increase in age, one would expect an 8.9% reduction in LOS (exp(-0.093) = 0.911). Those intubated before transplantation had a 15.82% increase in LOS over those who were not intubated (exp(0.1469) = 1.158). There was a 63% decrease in LOS for those who died within 30 days (exp(-1.0038) = 0.366). For each 10% increase in days on postoperative ventilator support, one would expect a 2.52% increase in the LOS (1.1<sup>0.2612</sup> = 1.025) and for each 10% increase in days on postoperative vasoactive support, one would expect a 15.82% increase in the LOS (1.1<sup>0.1468</sup> = 1.1582).

**Table 7. Multiple Regression Analysis of 282 Infant Heart Transplant Recipients Who Survived >30 Days on Log Length of Stay**

Variable	β	Confidence interval	P value
RBC (100 mL/kg)	-0.081	2.706 to 3.433	0.271
1995–2012 vs 1985–1994	0.076	-0.226 to 0.064	0.248
Log age (d)	-0.097	-0.053 to 0.204	<b>0.0016</b>
Log postoperative ventilator support (d)	0.296	-0.156 to -0.037	<b>&lt;0.0001</b>
Intubated before transplant	0.163	0.234 to 0.359	<b>0.012</b>
Intercept	3.07	0.036 to 0.289	<b>&lt;0.0001</b>

Bold indicates significance; adjusted R<sup>2</sup> = 0.3604. Final multiple regression model of factors influencing log length of stay (LOS) for 282 infants <1 year of age undergoing cardiac transplantation who survived >30 days postoperatively. The model indicates that there is no impact of intraoperative red blood cell (RBC) transfusion on LOS. For every 10% increase in age, one would expect a 0.91% decrease in LOS. Those intubated before transplantation had a 17.70% increase in LOS compared with those who were not intubated (exp(0.16268) = 1.1767). For each 10% increase in days of postoperative ventilator support, one would expect a 3.44% increase in the LOS (1.1<sup>0.29615</sup> = 1.344).

in the pediatric patients randomly assigned to a restrictive approach. This meta-analysis also reported numerically more adverse events (death, stroke, and infections) in the restrictive group.<sup>31</sup> A review of the literature searching for prospective studies involving RBC transfusion management during surgery for the repair of congenital heart disease in the pediatric population found only a small number of heterogeneous trials with insufficient evidence to assess the outcome impact of RBC transfusions in this subgroup.<sup>32</sup>

The lowest “safe” hematocrit during CPB has yet to be determined, and there is some evidence that intraoperative anemia may be associated with negative outcomes. A randomized trial in infants <9 months of age to assess the effect of hemodilution (goal hematocrit 20% vs 30%) before low-flow CPB during cardiac surgery found that during the postoperative period the low hematocrit group had decreased

**Table 8. Univariate Logistic Regression Modeling of Variables Related to 30-Day Mortality**

Effect	Odds ratio estimates				R <sup>2</sup>	H-L $\chi^2$ P value
	Point estimate	95% Wald confidence limits		Wald P value		
RBC (100 mL/kg)	2.154	1.057	4.387	<b>0.0346</b>	0.0134	0.1891
Year of transplant: 1995–2012 vs 1985–1994	2.117	0.82	5.465	0.1210	0.0086	
Sex: female versus male	1.341	0.591	3.043	0.4835	0.0016	
Age at transplant (d)	1.001	0.996	1.006	0.7727	0.0003	0.8161
Log age at transplant (d)	1.146	0.772	1.7	0.4995	0.0015	0.8413
Weight at transplant (kg)	0.885	0.638	1.229	0.4670	0.0018	0.0971
Log weight at transplant (kg)	0.57	0.135	2.399	0.4432	0.0020	0.0921
Single-ventricle physiology: no versus yes	1.969	0.864	4.487	0.1068	0.0083	
Indication: cardiomyopathy: yes versus no	0.47	0.107	2.067	0.318	0.0039	
Indication: complex congenital heart disease: yes versus no	0.527	0.152	1.821	0.3109	0.0038	
Indication: other cardiac defect: yes versus no	2.896	0.311	26.948	0.3502	0.0023	
Preoperative hemoglobin (g/dL)	0.878	0.711	1.084	0.2248	0.005	0.1362
Intubated before transplant: yes versus no	0.642	0.248	1.661	0.3606	0.0029	
Preoperative prostaglandin infusion: no versus yes	0.83	0.335	2.057	0.6869	0.0005	
Preoperative inotrope score	0.995	0.909	1.09	0.9222	0	0.7628
Repeat sternotomy: yes versus no	1.513	0.537	4.26	0.4335	0.0019	
Donor organ ischemic time (min)	0.999	0.995	1.002	0.476	0.0017	0.3319
Circulatory arrest time (min)	1.019	0.998	1.04	0.0732	0.0113	0.0565
Cardiopulmonary bypass time (min)	1.002	0.993	1.011	0.6856	0.0005	0.8754
Postoperative hemoglobin (g/dL)	1.07	0.871	1.315	0.5202	0.0014	0.1529
Postoperative ventilator support (d)	0.992	0.952	1.033	0.6814	0	0.5589
Log postoperative ventilator support (d)	0.996	0.657	1.509	0.9853	0	0.7346
Above versus below median postoperative ventilator support (d)	1.322	0.583	2.999	0.5039	0.0015	
Postoperative vasoactive support (d)	0.999	0.949	1.053	0.9846	0	0.2458
Log postoperative vasoactive support (d)	0.906	0.525	1.565	0.7246	0.0004	0.2390
Above versus below median postoperative vasoactive support (d)	1.103	0.486	2.503	0.8139	0.0002	
Reoperation other than open chest closure: yes versus no	7.105	2.401	21.023	<b>0.0004</b>	0.0328	
Postoperative cardiac arrest	13.682	5.598	33.438	<b>&lt;0.0001</b>	0.0973	
New postoperative dialysis	9.286	3.769	22.877	<b>&lt;0.0001</b>	0.0654	
New postoperative seizures	0.563	0.163	1.948	0.3643	0.0030	
Any postoperative major adverse event: yes versus no	23.75	5.482	102.9	<b>&lt;0.0001</b>	0.1106	

Univariate logistic regression modeling odds of 30-day mortality in 25 heart transplant recipient infants <1 year of age who died within 30 days of transplant compared to 282 who survived >30 days after transplant. One patient has missing data for time on CPB, so the analysis of CPB time contains one fewer. Bold values indicate significance; italic values indicate variables that do not hold well in the logistic regression analysis because of the small sample size. Log of odds was linear with the continuous independent variables. H-L  $\chi^2$  P value: Hosmer and Lemeshow goodness-of-fit test. Odds ratios were calculated as the odds of the outcome for the first listed categorical variable compared with the odds of the outcome for the second listed categorical variable.

cardiac index, higher serum lactate levels, and increased total body water, with no difference in total blood product exposure. Those evaluated in the low hematocrit group at 1 year of age demonstrated >0.5 SD lower Psychomotor Development Index scores.<sup>33</sup> The same group of investigators combined these results with a similar study evaluating the difference between hematocrit of 25% vs 35%, which demonstrated that decreased hematocrit before low-flow CPB was associated with increased intraoperative fluid balance and a slight increase in lactate levels 60 minutes after CPB. More importantly, there was a significant non-linear increase in Psychomotor Development Index scores at 1 year of age with increasing hematocrit (plateauing at hematocrit of 23.5%), raising concern regarding the practice of extreme hemodilution to minimize blood transfusion in infant cardiac surgery.<sup>34,35</sup>

Our analysis showed that age and weight significantly correlate with LOS. This demonstrates the importance of comparing the outcome impact of RBC transfusion within

specific age groups to minimize sampling bias. Additional studies are needed to address the effects of blood transfusion strategies in varied pediatric subgroups, because age and size are linked to estimated blood volume, the resultant dilutional effect of CPB circuit prime, and the amount of physiologic reserve. Infants are more likely to have cyanotic heart disease, require more complex repairs, and have longer duration of CPB and cross-clamp times, which results in increased nonhemostatic thrombin generation, fibrin degradation, and subsequent increased bleeding.<sup>36</sup>

Weaknesses of this study include its retrospective design over an extended period during which changes have occurred in the approach to infant heart transplantation, blood product storage, and hospital discharge criteria. We have addressed this by evaluating outcomes based on the year of transplant and before-and-after implementation of selective cerebral perfusion during CPB. However, it is possible that other confounding variables remain unaccounted for in this study. There were transfusion guidelines that specified a target



**Table 9. Bivariate Logistic Regression Modeling of Variables Related to 30-Day Mortality**

Odds ratio estimates							
Model	Effect	Point estimate	95% Wald confidence limits		Wald P value	R <sup>2</sup>	H-L $\chi^2$ P value
0	RBC (100 mL/kg)	1.08	1.006	1.159	0.0346	0.0134	0.1891
1	RBC (100 mL/kg)	1.867	0.837	4.166	0.1272	0.0156	0.2256
	1995–2012 vs 1985–1994	1.533	0.54	4.348	0.4221		
2	RBC (100 mL/kg)	2.138	1.045	4.372	0.0374	0.0146	0.2886
	Sex: female versus male	1.291	0.565	2.95	0.5449		
3	RBC (100 mL/kg)	2.764	1.256	6.083	0.0115	0.0193	0.6326
	Age at transplant days	1.004	0.998	1.01	0.1591		
4	RBC (100 mL/kg)	2.875	1.332	6.205	0.0071	0.0230	0.0258
	Log age at transplant days	1.493	0.931	2.395			
5	RBC (100 mL/kg)	2.705	1.067	6.857	0.036	0.0152	0.8544
	Weight at transplant kg	1.167	0.78	1.745	0.4519		
6	RBC (100 mL/kg)	2.918	1.083	7.863	0.0342	0.0158	0.7332
	Log weight at transplant kg	2.385	0.329	17.297	0.3900		
7	RBC (100 mL/kg)	2.126	1.037	4.359	0.0394	0.0209	0.5111
	Single-ventricle physiology: no versus yes	1.925	0.839	4.418	0.122		
8	RBC (100 mL/kg)	2.032	0.995	4.28	0.0620	0.0144	0.9239
	Transplant for cardiomyopathy: yes versus no	0.662	0.143	3.068	0.5984		
9	RBC (100 mL/kg)	2.154	1.063	4.365	0.0332	0.0175	0.8644
	Transplant for complex congenital heart disease	0.516	0.148	1.792	0.2972		
10	RBC (100 mL/kg)	2.225	1.088	4.551	0.0285	0.0167	0.1394
	Other cardiac defect leading to transplant: yes versus no	3.729	0.388	35.799	0.2541		
11	RBC (100 mL/kg)	2.398	1.155	4.981	0.0190	0.0219	0.4459
	Preoperative hemoglobin	0.845	0.682	1.047	0.1233		
12	RBC (100 mL/kg)	2.201	1.075	4.507	0.0309	0.0169	0.3875
	Intubated before transplant: yes versus no	0.611	0.234	1.596	0.3149		
13	RBC (100 mL/kg)	2.182	1.05	4.534	0.0366	0.0135	0.6282
	Preoperative prostaglandin infusion: no versus yes	1.072	0.417	2.757	0.8857		
14	RBC (100 mL/kg)	2.283	1.088	4.789	0.0291	0.0143	0.5776
	Preoperative inotrope score	1.025	0.941	1.116	0.5726		
15	RBC (100 mL/kg)	1.083	1.009	1.163	0.0275	0.0164	0.5122
	Repeat sternotomy: yes versus no	1.716	0.599	4.916	0.3149		
16	RBC (100 mL/kg)	2.142	1.052	4.362	0.0358	0.0149	0.3319
	Donor organ ischemic time (min)	0.999	0.995	1.002	0.4980		
17	RBC (100 mL/kg)	1.774	0.779	4.038	0.1720	0.0169	0.7102
	Circulatory arrest time (min)	1.012	0.989	1.035	0.3112		
18	RBC (100 mL/kg)	2.225	1.098	4.629	0.0267	0.0151	0.8753
	Cardiopulmonary bypass time (min)	1.004	0.994	1.013	0.4313		
19	RBC (100 mL/kg)	2.138	1.037	4.409	0.0396	0.0142	0.3434
	Postoperative hemoglobin (g/dL)	1.022	0.828	1.261	0.8408		
20	RBC (100 mL/kg)	2.203	1.07	4.53	0.0320	0.0151	0.5396
	Postoperative ventilator support (d)	0.986	0.93	1.046	0.6443		
21	RBC (100 mL/kg)	2.277	1.08	4.801	0.0306	0.0143	0.2934
	Log postoperative ventilator support (d)	0.884	0.556	1.408	0.6048		
22	RBC (100 mL/kg)	2.112	1.014	4.40	0.0458	0.0136	0.7961
	Above versus below median postoperative ventilator support (d)	1.096	0.468	2.565	0.8331		
23	RBC (100 mL/kg)	2.201	1.07	4.53	0.0321	0.0139	0.9312
	Postoperative vasoactive support (d)	0.989	0.92	1.063	0.7695		
24	RBC (100 mL/kg)	2.399	1.143	5.033	0.0207	0.0166	0.9917
	Log postoperative vasoactive support (d)	0.752	0.421	1.344	0.3365		
25	RBC (100 mL/kg)	2.201	1.061	4.564	0.0340	0.0137	0.8866
	Above versus below median postoperative vasoactive support (d)	0.901	0.385	2.106	0.8092		
26	RBC (100 mL/kg)	1.977	0.941	4.154	0.0720	0.0423	0.5950
	Reoperation other than delayed chest closure	6.436	2.138	19.374	0.0009		
27	RBC (100 mL/kg)	1.983	0.897	4.47	0.0989	0.1051	0.7569
	Postoperative cardiac arrest: yes versus no	13.134	5.324	32.402	<0.0001		
28	RBC (100 mL/kg)	1.821	0.847	3.915	0.1249	0.0723	0.4158
	New postoperative dialysis	8.575	3.439	21.384	<0.0001		
29	RBC (100 mL/kg)	2.134	1.047	4.351	0.0369	0.0161	0.2149
	New postoperative seizures	0.576	0.165	2.01	0.3872		
30	RBC (100 mL/kg)	1.793	0.834	3.854	0.1350	0.1168	0.7212
	Any major adverse event: yes versus no	22.503	5.179	97.775	<0.0001		

Bivariate logistic regression modeling of variables related to 30-day mortality in 25 heart transplant recipient infants <1 year of age who died within 30 days of transplant compared with 282 who survived >30 days after transplant. One patient has missing data for time on CPB, so the analysis of CPB time contains one fewer. Bold values indicate significance; italic values indicate variables that do not hold well in the logistic regression analysis because of the small sample size. Log of odds was linear with the continuous independent variables. H-L  $\chi^2$  P value: Hosmer and Lemeshow goodness-of-fit test. Odds ratios were calculated as the odds of the outcome for the first listed categorical variable compared with the odds of the outcome for the second listed categorical variable.

postoperative hemoglobin, and the postoperative hemoglobin was within the target range on average. However, this target range was not met in all patients. Washed irradiated RBCs were used per protocol, so there was no control group to evaluate whether this practice affected outcomes. Both lactate and potassium levels rise during blood storage, and the standard protocol for RBC transfusion in transplant recipients involves irradiation, which further weakens the RBC membrane, increasing potassium leakage. Washing irradiated RBCs can reduce potassium and lactate loads, prevent hyperkalemia in infants during CPB, and remove prestorage additives (which may have an unknown effect on the neonate).<sup>37-39</sup> This is also an area in need of further research.

There are other limitations to generalizing our findings. Tranexamic acid was not part of the perioperative protocol for infant cardiac transplant, because the risk-benefit ratio in pediatric cardiac surgery had not been adequately established.<sup>40</sup> Our study design did not include RBC transfusion or chest tube output during the first 48 hours postoperatively, which could have provided additional pertinent information. The Index for Mortality Prediction After Cardiac Transplantation (IMPACT) score<sup>41</sup> was not used, because it was not suitable to distinguish differences within our specific patient population.

Pediatric transfusion medicine is a developing field with large gaps in evidence-based practice.<sup>42</sup> Whether increased blood transfusion is the cause of increased morbidity or simply a marker of it remains unclear. Neonates and infants are an important subgroup within the pediatric population requiring unique consideration to account for their maturing organ systems, decreased physiologic reserve, and increased surgical blood loss and RBC transfusion requirement (in mL/kg) compared with their larger counterparts. This retrospective study of RBC transfusion to infants undergoing heart transplantation failed to show a positive correlation between intraoperative RBC transfusion volume and postoperative LOS, while decreased age (which directly correlated with weight) was an independent predictor of increased LOS. The difference in outcomes between this and a prior report<sup>5</sup> highlights the possibility of sampling bias in pediatric studies covering a large developmental time period including patients from the first day of life to 18 years of age. Additional prospective studies are needed to determine the outcome impact of RBC transfusion strategies to infants as a unique pediatric subgroup. ■

#### DISCLOSURES

**Name:** Harmony F. Carter, MD.

**Contribution:** This author participated in study design, study conduct, data collection, data analysis, and manuscript preparation.

**Attestation:** Harmony F. Carter approved the final manuscript and attests to the integrity of the original data and the analysis reported in this manuscript.

**Name:** Carol Lau, MD.

**Contribution:** This author participated in study design, study conduct, data collection, data analysis, and manuscript preparation.

**Attestation:** Carol Lau approved the final manuscript and attests to the integrity of the original data and the analysis reported in this manuscript.

**Name:** David Juma, MPH.

**Contribution:** This author participated in data analysis and manuscript preparation.

**Attestation:** David Juma approved the final manuscript and attests to the integrity of the original data and the analysis reported in this manuscript.

**Name:** Briana Wells, MS.

**Contribution:** This author participated in data analysis and manuscript preparation.

**Attestation:** Briana Wells approved the final manuscript and attests to the integrity of the original data and the analysis reported in this manuscript.

**Name:** Richard L. Applegate II, MD.

**Contribution:** This author participated in study design, study conduct, data collection, data analysis, and manuscript preparation.

**Attestation:** Richard L. Applegate II approved the final manuscript and attests to the integrity of the original data and the analysis reported in this manuscript and is also the archival author.

**This manuscript was handled by:** James DiNardo, MD.

#### ACKNOWLEDGMENTS

The authors express appreciation to those who made significant contributions to this article. Keiji Oda, MA, MPH, assisted with much of the initial statistical analysis. Leonard Bailey, MD, provided insights into this institution's history and practice of infant heart transplantation including details regarding cardiopulmonary bypass management changes over time. Finally, thanks to James Fitts and the International Heart Institute for sharing from their extensive database.

#### REFERENCES

- Guzzetta NA. Benefits and risks of red blood cell transfusion in pediatric patients undergoing cardiac surgery. *Paediatr Anaesth* 2011;21:504-11
- Richmond ME, Charette K, Chen JM, Quaegebeur JM, Bacha E. The effect of cardiopulmonary bypass prime volume on the need for blood transfusion after pediatric cardiac surgery. *J Thorac Cardiovasc Surg* 2013;145:1058-64
- Bhaskar B, Dulhunty J, Mullany DV, Fraser JF. Impact of blood product transfusion on short and long-term survival after cardiac surgery: more evidence. *Ann Thorac Surg* 2012;94:460-7
- Costello JM, Graham DA, Morrow DE, Morrow J, Potter-Bynoe G, Sandora TJ, Pigula FA, Laussen PC. Risk factors for surgical site infection after cardiac surgery in children. *Ann Thorac Surg* 2010;89:1833-41
- Howard-Quijano K, Schwarzenberger JC, Scovotti JC, Alejos A, Ngo J, Gornbein J, Mahajan A. Increased red blood cell transfusions are associated with worsening outcomes in pediatric heart transplant patients. *Anesth Analg* 2013;116:1295-308
- Iyengar A, Scipione CN, Sheth P, Ohye RG, Riegger L, Bove EL, Devaney EJ, Hirsch-Romano JC. Association of complications with blood transfusions in pediatric cardiac surgery patients. *Ann Thorac Surg* 2013;96:910-6
- Kipps AK, Wypij D, Thiagarajan RR, Bacha EA, Newburger JW. Blood transfusion is associated with prolonged duration of mechanical ventilation in infants undergoing reparative cardiac surgery. *Pediatr Crit Care Med* 2011;12:52-6
- Kneyber MC, Hersi MI, Twisk JW, Markhorst DG, Plötz FB. Red blood cell transfusion in critically ill children is independently associated with increased mortality. *Intensive Care Med* 2007;33:1414-22
- Salvin JW, Scheurer MA, Laussen PC, Wypij D, Polito A, Bacha EA, Pigula FA, McGowan FX, Costello JM, Thiagarajan RR. Blood transfusion after pediatric cardiac surgery is associated with prolonged hospital stay. *Ann Thorac Surg* 2011;91:204-10
- Székely A, Cserép Z, Sági E, Breuer T, Nagy CA, Vargha P, Hartvánszky I, Szatmári A, Treszl A. Risks and predictors of

- blood transfusion in pediatric patients undergoing open heart operations. *Ann Thorac Surg* 2009;87:187–97
11. Lacroix J, Hébert PC, Hutchison JS, Hume HA, Tucci M, Ducruet T, Gauvin F, Collet JP, Toledano BJ, Robillard P, Joffe A, Biarent D, Meert K, Peters MJ; TRIPICU Investigators; Canadian Critical Care Trials Group; Pediatric Acute Lung Injury and Sepsis Investigators Network. Transfusion strategies for patients in pediatric intensive care units. *N Engl J Med* 2007;356:1609–19
  12. Willems A, Harrington K, Lacroix J, Biarent D, Joffe AR, Wensley D, Ducruet T, Hébert PC, Tucci M; TRIPICU investigators; Canadian Critical Care Trials Group; Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network. Comparison of two red-cell transfusion strategies after pediatric cardiac surgery: a subgroup analysis. *Crit Care Med* 2010;38:649–56
  13. Jacobs JP, Quintessenza JA, Boucek RJ, Morell VO, Botero LM, Badhwar V, van Gelder HM, Asante-Korang A, McCormack J, Daicoff GR. Pediatric cardiac transplantation in children with high panel reactive antibody. *Ann Thorac Surg* 2004;78:1703–9
  14. Shaddy RE, Fuller TC. The sensitized pediatric heart transplant candidate: causes, consequences, and treatment options. *Pediatr Transplant* 2005;9:208–14
  15. Dipchand AI, Edwards LB, Kucheryavaya AY, Benden C, Dobbels F, Levvey BJ, Lund LH, Meiser B, Yussen RD, Stehlik J; International Society of Heart and Lung Transplantation. The registry of the International Society for Heart and Lung Transplantation: seventeenth official pediatric heart transplantation report—2014; focus theme: retransplantation. *J Heart Lung Transplant* 2014;33:985–95
  16. Fan X, Ang A, Pollock-Barziv SM, Dipchand AI, Ruiz P, Wilson G, Platt JL, West LJ. Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation. *Nat Med* 2004;10:1227–33
  17. Henderson HT, Canter CE, Mahle WT, Dipchand AI, LaPorte K, Schechtman KB, Zheng J, Asante-Korang A, Singh RK, Kanter KR. ABO-incompatible heart transplantation: analysis of the Pediatric Heart Transplant Study (PHTS) database. *J Heart Lung Transplant* 2012;31:173–9
  18. West LJ. Defining critical windows in the development of the human immune system. *Hum Exp Toxicol* 2002;21:499–505
  19. Bailey LL. Deep hypothermia and total circulatory arrest for cardiac surgery. In: Wu Y, Peters MP, ed. *International Practice in Cardiothoracic Surgery*. Beijing, China: Science Press, 1985:135–44
  20. Razzouk A, Hasaniya N, Bailey LL. Classic single-patch repair of atrioventricular septal defects. *Oper Tech Thorac Cardiovasc Surg* 2015;20:75–86
  21. Dexter F, Kern FH, Hindman BJ, Greeley WJ. The brain uses mostly dissolved oxygen during profoundly hypothermic cardiopulmonary bypass. *Ann Thorac Surg* 1997;63:1725–9
  22. Lavoie J. Blood transfusion risks and alternative strategies in pediatric patients. *Paediatr Anaesth* 2011;21:14–24
  23. Bhananker SM, Ramamoorthy C, Geiduschek JM, Posner KL, Domino KB, Haberkern CM, Campos JS, Morray JP. Anesthesia-related cardiac arrest in children: update from the Pediatric Perioperative Cardiac Arrest Registry. *Anesth Analg* 2007;105:344–50
  24. Williams GD, Bratton SL, Riley EC, Ramamoorthy C. Association between age and blood loss in children undergoing open heart operations. *Ann Thorac Surg* 1998;66:870–5
  25. Agarwal HS, Barrett SS, Barry K, Xu M, Saville BR, Donahue BS, Harris ZL, Bichell DP. Association of blood products administration during cardiopulmonary bypass and excessive postoperative bleeding in pediatric cardiac surgery. *Pediatr Cardiol* 2015;36:459–67
  26. Redlin M, Habazettl H, Boettcher W, Kukucka M, Schoenfeld H, Hetzer R, Huebler M. Effects of a comprehensive blood-sparing approach using body weight-adjusted miniaturized cardiopulmonary bypass circuits on transfusion requirements in pediatric cardiac surgery. *J Thorac Cardiovasc Surg* 2012;144:493–9
  27. Redlin M, Kukucka M, Boettcher W, Schoenfeld H, Huebler M, Kuppe H, Habazettl H. Blood transfusion determines postoperative morbidity in pediatric cardiac surgery applying a comprehensive blood-sparing approach. *J Thorac Cardiovasc Surg* 2013;146:537–42
  28. Karimi M, Florentino-Pineda I, Weatherred T, Qadeer A, Rosenberg CA, Hudacko A, Ryu D. Blood conservation operations in pediatric cardiac patients: a paradigm shift of blood use. *Ann Thorac Surg* 2013;95:962–7
  29. Karkouti K, Stukel TA, Beattie WS, Elsaadany S, Li P, Berger R, Wijesundera DN. Relationship of erythrocyte transfusion with short- and long-term mortality in a population-based surgical cohort. *Anesthesiology* 2012;117:1175–83
  30. Dixon B, Santamaria JD, Reid D, Collins M, Rechnitzer T, Newcomb AE, Nixon I, Yui M, Rosalion A, Campbell DJ. The association of blood transfusion with mortality after cardiac surgery: cause or confounding? (CME). *Transfusion* 2013;53:19–27
  31. Curley GF, Shehata N, Mazer CD, Hare GM, Friedrich JO. Transfusion triggers for guiding RBC transfusion for cardiovascular surgery: a systematic review and meta-analysis\*. *Crit Care Med* 2014;42:2611–24
  32. Wilkinson KL, Brunskill SJ, Doree C, Trivella M, Gill R, Murphy MF. Red cell transfusion management for patients undergoing cardiac surgery for congenital heart disease. *Cochrane Database Syst Rev* 2014;2:CD009752
  33. Jonas RA, Wypij D, Roth SJ, Bellinger DC, Visconti KJ, du Plessis AJ, Goodkin H, Laussen PC, Farrell DM, Bartlett J, McGrath E, Rappaport LJ, Bacha EA, Forbess JM, del Nido PJ, Mayer JE Jr, Newburger JW. The influence of hemodilution on outcome after hypothermic cardiopulmonary bypass: results of a randomized trial in infants. *J Thorac Cardiovasc Surg* 2003;126:1765–74
  34. Newburger JW, Jonas RA, Soul J, Kussman BD, Bellinger DC, Laussen PC, Robertson R, Mayer JE Jr, del Nido PJ, Bacha EA, Forbess JM, Pigula F, Roth SJ, Visconti KJ, du Plessis AJ, Farrell DM, McGrath E, Rappaport LA, Wypij D. Randomized trial of hematocrit 25% versus 35% during hypothermic cardiopulmonary bypass in infant heart surgery. *J Thorac Cardiovasc Surg* 2008;135:347–54, 354.e1–4
  35. Wypij D, Jonas RA, Bellinger DC, Del Nido PJ, Mayer JE Jr, Bacha EA, Forbess JM, Pigula F, Laussen PC, Newburger JW. The effect of hematocrit during hypothermic cardiopulmonary bypass in infant heart surgery: results from the combined Boston hematocrit trials. *J Thorac Cardiovasc Surg* 2008;135:355–60
  36. Eisses MJ, Chandler WL. Cardiopulmonary bypass parameters and hemostatic response to cardiopulmonary bypass in infants versus children. *J Cardiothorac Vasc Anesth* 2008;22:53–9
  37. Cholette JM, Henrichs KF, Alfieri GM, Powers KS, Phipps R, Spinelli SL, Swartz M, Gensini F, Daugherty LE, Nazarian E, Rubenstein JS, Sweeney D, Eaton M, Lerner NB, Blumberg N. Washing red blood cells and platelets transfused in cardiac surgery reduces postoperative inflammation and number of transfusions: results of a prospective, randomized, controlled clinical trial. *Pediatr Crit Care Med* 2012;13:290–9
  38. Sloan SR. Neonatal transfusion review. *Paediatr Anaesth* 2011;21:25–30
  39. Swindell CG, Barker TA, McGuirk SP, Jones TJ, Barron DJ, Brawn WJ, Horsburgh A, Willetts RG. Washing of irradiated red blood cells prevents hyperkalemia during cardiopulmonary bypass in neonates and infants undergoing surgery for complex congenital heart disease. *Eur J Cardiothorac Surg* 2007;31:659–64
  40. Faraoni D, Willems A, Melot C, De Hert S, Van der Linden P. Efficacy of tranexamic acid in paediatric cardiac surgery: a systematic review and meta-analysis. *Eur J Cardiothorac Surg* 2012;42:781–6
  41. Kilic A, Allen JG, Arnaoutakis GJ, George TJ, Cameron DE, Vricella LA, Weiss ES. Adult-derived Index for Mortality Prediction After Cardiac Transplantation (IMPACT) risk score predicts short-term mortality after pediatric heart transplantation. *Ann Thorac Surg* 2012;93:1228–34
  42. Josephson CD, Mondoro TH, Ambruso DR, Sanchez R, Sloan SR, Luban NL, Widness JA. One size will never fit all: the future of research in pediatric transfusion medicine. *Pediatr Res* 2014;76:425–31